Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients
Authors:
- 1 January 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (5) , 2143-2148
Abstract
The Vav3 oncogene is overexpressed and has a significant role in the tumorigenesis of prostate cancer and glioblastoma. In the present study, the expression status and prognostic value of Vav3 expression was investigated in breast cancer. Vav3 protein levels were analyzed by immunoblotting in human breast cancer and epithelial cell lines. Immunohistochemistry was used to detect Vav3 in a tissue microarray of 173 breast cancers and 19 benign breast lesions. Statistical analysis was performed to reveal the association between Vav3 expression and clinicopathological parameters. Disease‑free survival (DFS) and overall survival (OS) were calculated by Kaplan‑Meier analysis and the Cox regression model. The Vav3 protein level was higher in the breast cancer cell lines than in the normal human breast cells. Vav3 was expressed in 86.1% of breast cancer patients, but in only 15.6% patients with benign breast disease. Patients with negative estrogen receptor expression, axillary lymph node involvement and a high tumor-node-metastasis stage demonstrated a higher positive rate of Vav3 expression. The Kaplan‑Meier survival analysis revealed that patients with higher Vav3 expression exhibited shorter DFS and OS times. The multivariate Cox analysis revealed that Vav3 was a prognostic factor of survival. Overall, Vav3 was overexpressed in human breast cancer cells and this correlated with a shorter survival time, indicating that Vav3 is a biomarker of a poor prognosis for breast cancer patients.Keywords
This publication has 25 references indexed in Scilit:
- Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancerEndocrine-Related Cancer, 2010
- Prediction of epigenetically regulated genes in breast cancer cell linesBMC Bioinformatics, 2010
- The Guanine Nucleotide Exchange Factors Trio, Ect2, and Vav3 Mediate the Invasive Behavior of GlioblastomaThe American Journal of Pathology, 2008
- Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine KinaseJournal of Biological Chemistry, 2008
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98Journal of Clinical Oncology, 2007
- Essential Role of Vav Family Guanine Nucleotide Exchange Factors in EphA Receptor-Mediated AngiogenesisMolecular and Cellular Biology, 2006
- Tissue microarrays in drug discoveryNature Reviews Drug Discovery, 2003
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- The VAV Family of Signal Transduction MoleculesCritical Reviews™ in Oncogenesis, 1996